SEC Filing Summary: Sanofi (13F-HR)
Business Context and Reporting Period
This filing is a Form 13F-HR submitted by Sanofi, an institutional investment manager based in Paris, France. The report covers the quarter ended June 30, 2026, and was signed on July 28, 2026, by Alexandra Roger, Head of Legal Corporate & Finance.
Key Financial Metrics
As a Form 13F-HR, this document discloses equity holdings rather than the company's operational financial performance. Consequently, the filing does not provide data on Sanofi's revenue, profit, cash flow, margins, debt, or liquidity.
- Total Value of Reported Holdings: $534,041,662
- Number of Holdings Reported: 10
- Other Included Managers: None
Material Changes
The filing text does not provide comparative data against the prior period (March 31, 2026) to determine material changes in holdings or value. The document lists only the current quarter's snapshot.
Guidance, Outlook, and Risks
This form is a regulatory disclosure of investment positions and does not contain management commentary, future guidance, risk factors, or contingencies regarding Sanofi's business operations.
Investor Verification Checklist
- Verify the specific 10 equity positions held by Sanofi's investment arm, as the detailed list is not included in the summary text provided.
- Confirm whether the $534 million in reported holdings represents a significant portion of Sanofi's total investment portfolio or if other managers report additional holdings.
- Note that this filing reflects Sanofi's role as an investor, not its performance as a pharmaceutical company; refer to 10-K or 20-F filings for operational metrics.